Prediction of clinical pharmacokinetics of AMG 181, a human anti-α4β7 monoclonal antibody for treating inflammatory bowel diseases

@inproceedings{Li2015PredictionOC,
  title={Prediction of clinical pharmacokinetics of AMG 181, a human anti-α4β7 monoclonal antibody for treating inflammatory bowel diseases},
  author={Hong Li and Kathleen K{\"o}ck and John A Wisler and William A. Rees and Peter J Prince and Kai O Reynhardt and Hailing Hsu and Zhigang Yu and Dominic C. Borie and David H. Salinger and Wei-Jian Pan},
  booktitle={Pharmacology research & perspectives},
  year={2015}
}
The purpose of this study was to predict a safe starting dose of AMG 181, a human anti-α 4 β 7 antibody for treating inflammatory bowel diseases, based on cynomolgus monkey pharmacokinetic (PK) and pharmacodynamic (PD) data. A two-compartment model with parallel linear and target-mediated drug disposition for AMG 181 PK in cynomolgus monkey was developed. The estimated parameters were allometrically scaled to predict human PK. An E max PD model was used to relate AMG 181 concentration and free… CONTINUE READING
2 Citations
40 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, Vol

  • FDA
  • 2012, 7/6/2005 edn. US Food and Drug…
  • 2005
Highly Influential
4 Excerpts

NONMEM user’s guides (1989–2009)

  • SS Beal, LB Boeckmann, RJ Bauer
  • ICON Development Solutions, Ellicott City, MD.
  • 2009
Highly Influential
2 Excerpts

Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products, Vol

  • EMA
  • 2012, 3/6/2007 edn. Committee for Medicinal…
  • 2007
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…